Langerhans’-cell histiocytosis (LCH) is a rare disorder characterized by tissue infiltrates of CD1a+ Langerhans’ cells, eosinophils, neutrophils, macrophages, and lymphocytes. Systemic treatments for refractory LCH are unsatisfactory and usually toxic. We report the use of imatinib mesylate to control parenchymal brain involvement in a patient with multisystem LCH.
Imatinib mesylate for cerebral Langerhans'-cell histiocytosis / Montella, L; Insabato, Luigi; Palmieri, Giovannella. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - STAMPA. - 351:10(2004), pp. 1034-1035.
Imatinib mesylate for cerebral Langerhans'-cell histiocytosis.
INSABATO, LUIGI;PALMIERI, GIOVANNELLA
2004
Abstract
Langerhans’-cell histiocytosis (LCH) is a rare disorder characterized by tissue infiltrates of CD1a+ Langerhans’ cells, eosinophils, neutrophils, macrophages, and lymphocytes. Systemic treatments for refractory LCH are unsatisfactory and usually toxic. We report the use of imatinib mesylate to control parenchymal brain involvement in a patient with multisystem LCH.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Imatinib mesylate 2004.pdf
non disponibili
Tipologia:
Documento in Post-print
Licenza:
Accesso privato/ristretto
Dimensione
166.58 kB
Formato
Adobe PDF
|
166.58 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
